Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism

Blood

Volumn 129, Issue 13, 2017, Pages 1831-1839

  Riedl, Julia ^a,b   Preusser, Matthias ^a,b   Nazari, Pegah Mir Seyed ^a,b   Posch, Florian ^a,b,c   Panzer, Simon ^a   Marosi, Christine ^a,b   Birner, Peter ^a   Thaler, Johannes ^a,b   Brostjan, Christine ^a   Lötsch, Daniela ^b,d   Berger, Walter ^b,d   Hainfellner, Johannes A ^a   Pabinger, Ingrid ^a,b   Ay, Cihan ^a,b,e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Central Nervous System Tumour Unit   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

D DIMER; PODOPLANIN; MEMBRANE PROTEIN; PDPN PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRAIN TUMOR; CARDIOVASCULAR RISK; COHORT ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; GLIOBLASTOMA CELL LINE; GLIOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PATIENT RISK; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; VENOUS THROMBOEMBOLISM; BIOSYNTHESIS; BLOOD; COMPLICATION; GLIOBLASTOMA; METABOLISM; PATHOLOGY; PROSPECTIVE STUDY; THROMBOPHILIA;

BRAIN NEOPLASMS; COHORT STUDIES; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; PLATELET AGGREGATION; PROSPECTIVE STUDIES; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 85018925879     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-06-720714     Document Type: Article

References (29)

1. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013; 122(10):1712-1723.
2. Semrad TJ, O’Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007;106(4):601-608.
3. Jo JT, Schiff D, Perry JR. Thrombosis in brain tumors. Semin Thromb Hemost. 2014;40(3): 325-331.
4. Brandes AA, Scelzi E, Salmistraro G, et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer. 1997;33(10):1592-1596.
5. Rodas RA, Fenstermaker RA, McKeever PE, et al. Correlation of intraluminal thrombosis in brain tumor vessels with postoperative thrombotic complications: a preliminary report. J Neurosurg. 1998;89(2):200-205.
6. Thaler J, Ay C, Kaider A, et al. Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. Neuro-oncol. 2014;16(12):1645-1651.
7. Baluk P, McDonald DM. Markers for microscopic imaging of lymphangiogenesis and angiogenesis. Ann N Y Acad Sci. 2008;1131:1-12.
8. Suzuki-Inoue K, Inoue O, Ozaki Y. Novel platelet activation receptor CLEC-2: from discovery to prospects. J Thromb Haemost. 2011;9(Suppl 1): 44-55.
9. Watson SP, Herbert JM, Pollitt AY. GPVI and CLEC-2 in hemostasis and vascular integrity. J Thromb Haemost. 2010;8(7):1456-1467.
10. Uhrin P, Zaujec J, Breuss JM, et al. Novel function for blood platelets and podoplanin in developmental separation of blood and lymphatic circulation. Blood. 2010; 115(19):3997-4005.
11. Shibahara J, Kashima T, Kikuchi Y, Kunita A, Fukayama M. Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch. 2006;448(4):493-499.
12. Ernst A, Hofmann S, Ahmadi R, et al. Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clin Cancer Res. 2009;15(21): 6541-6550.
13. Birner P, Pusch S, Christov C, et al. Mutant IDH1 inhibits PI3K/Akt signaling in human glioma. Cancer. 2014;120(16):2440-2447.
14. Chandramohan V, Bao X, Kato Kaneko M, et al. Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. Int J Cancer. 2013;132(10):2339-2348.
15. Suzuki-Inoue K, Kato Y, Inoue O, et al. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem. 2007;282(36): 25993-26001.
16. Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2008;112(7):2703-2708.
17. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4): 343-346.
18. Coviello VBM. Cumulative incidence estimation in the presence of competing risks. Stata J. 2004;4: 103-112.
19. Wolbers M, Koller MT, Stel VS, et al. Competing risks analyses: objectives and approaches. Eur Heart J. 2014;35(42):2936-2941.
20. Ay C, Posch F, Kaider A, Zielinski C, Pabinger I. Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality. J Thromb Haemost. 2015;13(3): 390-397.
21. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624): 806-808.
22. Thaler J, Preusser M, Ay C, et al. Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. Thromb Res. 2013;131(2):162-165.
23. Thaler J, Ay C, Mackman N, et al. Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost. 2012;10(7): 1363-1370.
24. Jurasz P, Alonso-Escolano D, Radomski MW. Platelet–cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol. 2004;143(7): 819-826.
25. Hitchcock JR, Cook CN, Bobat S, et al. Inflammation drives thrombosis after Salmonella infection via CLEC-2 on platelets. J Clin Invest. 2015;125(12):4429-4446.
26. Müller C, Holtschmidt J, Auer M, et al. Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med. 2014;6(247): 247ra101.
27. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell. 2006;9(4): 261-272.
28. Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T, Matsutani M. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol. 2006;111(5):483-488.
29. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6): 803-820.